Raptor Pharmaceutical Corp. (NASDAQ:RPTP) announced its earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.01, Analyst RN reports. The company had revenue of $10.20 million for the quarter. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares after opening at $13.88 on last trade day and at the end of the day closed at $11.25. Company price to sales ratio in past twelve months was calculated as 102.21 and price to cash ratio as 7.64. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) showed a negative weekly performance of -27.93%.
Dyax Corp. (NASDAQ:DYAX) announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $9.25 per share. The gross proceeds to Dyax from this offering are expected to be $74 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Dyax. The offering is expected to close on or about March 19, 2013, subject to customary closing conditions. Dyax Corp. (NASDAQ:DYAX) shares fell -9.11% in last trading session and ended the day on $9.23. DYAX return on equity ratio is recorded as 101.70% and its return on assets is -34.40%. Dyax Corp. (NASDAQ:DYAX) yearly performance is 126.23%.
Omeros Corporation (NASDAQ:OMER) announced that it has priced an underwritten public offering of 3,043,479 shares of its common stock at a price to the public of $11.50 per share for gross proceeds of $35.0 million. The net proceeds from the sale of the shares, after deducting the underwriters’ discounts and other estimated offering expenses, will be approximately $32.8 million. Omeros has also granted the underwriters a 30-day option to purchase up to an additional 456,521 shares of common stock to cover overallotments, if any, which would result in additional gross proceeds of approximately $5.2 million if exercised in full. Omeros Corporation (NASDAQ:OMER) shares moved down -7.72%in last trading session and was closed at $11.35, while trading in range of $11.00 – $11.59. Omeros Corporation (NASDAQ:OMER) year to date (YTD) performance is 0.53%.
Coronado Biosciences Inc (NASDAQ:CNDO) Reports Q4 (Jan) loss of ($0.27) per share, $0.04 worse than the Capital IQ Consensus of ($0.23); no revs. Research and development expenses were $25.7 mln for the year ended Dec 31, 2013, compared to $17.5 mln for 2012. General and administrative expenses totaled $10.1 mln for the year ended Dec 31, 2013, compared to $8.7 mln for 2012. In 2013, the increase in research and development expenses was due to expenses related to the TSO clinical program and the increase in general and administrative expenses related to incremental personnel-related costs from the elimination of certain executive positions and the departure of Coronado’s previous CEO. At Dec 31, 2013, Coronado’s cash and cash equivalents totaled $99.5 mln.Coronado Biosciences Inc (NASDAQ:CNDO) weekly performance is -14.07%. On last trading day company shares ended up $2.26. Coronado Biosciences Inc (NASDAQ:CNDO) distance from 50-day simple moving average (SMA50) is -17.03%. Analysts mean target price for the company is $1.90.